Endogenous hepcidin and its agonist mediate resistance to selected infections by clearing non–transferrin-bound iron

Blood

Volumn 130, Issue 3, 2017, Pages 245-257

  Stefanova, Deborah ^a   Raychev, Antoan ^b   Arezes, Joao ^c   Ruchala, Piotr ^b   Gabayan, Victoria ^b   Skurnik, Mikael ^d   Dillon, Barbara J ^b   Horwitz, Marcus A ^b   Ganz, Tomas ^b   Bulut, Yonca ^b   Nemeth, Elizabeta ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF OXFORD   (United Kingdom)

^d UNIVERSITY OF HELSINKI   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

HEPCIDIN; IRON; IRON DEXTRAN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MESSENGER RNA; NON TRANSFERRIN BOUND IRON; UNCLASSIFIED DRUG; HAMP1 PROTEIN, MOUSE; OLIGOPEPTIDE; PROTEIN BINDING; TRANSFERRIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BACTERIAL GROWTH; BACTERIAL LOAD; BACTERIAL VIRULENCE; BACTERICIDAL ACTIVITY; CATHETER INFECTION; COLONY FORMATION; CONTROLLED STUDY; EXTRACELLULAR MATRIX; IN VITRO STUDY; INFECTION RESISTANCE; INNATE IMMUNITY; IRON BLOOD LEVEL; IRON DEPLETION; IRON OVERLOAD; LUNG TUBERCULOSIS; MORTALITY; MOUSE; MOUTH INFECTION; MYCOBACTERIUM TUBERCULOSIS; NEUTROPHIL; NONHUMAN; PRIORITY JOURNAL; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS INFECTION; YERSINIA ENTEROCOLITICA; YERSINIOSIS; AGONISTS; ANIMAL; BINDING COMPETITION; C57BL MOUSE; DEFICIENCY; DISEASE MODEL; DISEASE RESISTANCE; DRUG EFFECTS; GENE EXPRESSION; GENETICS; GROWTH, DEVELOPMENT AND AGING; HEMOCHROMATOSIS; HUMAN; IMMUNOLOGY; KNOCKOUT MOUSE; METABOLISM; MICROBIOLOGY; SURVIVAL ANALYSIS;

ANIMALS; BINDING, COMPETITIVE; CATHETER-RELATED INFECTIONS; DISEASE MODELS, ANIMAL; DISEASE RESISTANCE; GENE EXPRESSION; HEMOCHROMATOSIS; HEPCIDINS; HUMANS; IRON; IRON OVERLOAD; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MYCOBACTERIUM TUBERCULOSIS; OLIGOPEPTIDES; PROTEIN BINDING; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS; SURVIVAL ANALYSIS; TRANSFERRIN; YERSINIA ENTEROCOLITICA;

EID: 85026309818     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2017-03-772715     Document Type: Article

References (31)

1. Rodriguez R, Jung CL, Gabayan V, et al. Hepcidin induction by pathogens and pathogen-derived molecules is strongly dependent on interleukin-6. Infect Immun. 2014;82(2): 745-752.
2. Nemeth E, Ganz T. Regulation of iron metabolism by hepcidin. Annu Rev Nutr. 2006;26:323-342.
3. Christopher GW. Escherichia coli bacteremia, meningitis, and hemochromatosis. Arch Intern Med. 1985;145(10):1908.
4. Gerhard GS, Levin KA, Price Goldstein J, Wojnar MM, Chorney MJ, Belchis DA. Vibrio vulnificus septicemia in a patient with the hemochromatosis HFE C282Y mutation. Arch Pathol Lab Med. 2001;125(8):1107-1109.
5. Manso C, Rivas I, Peraire J, Vidal F, Richart C. Fatal Listeria meningitis, endocarditis and pericarditis in a patient with haemochromatosis. Scand J Infect Dis. 1997;29(3):308-309.
6. Vadillo M, Corbella X, Pac V, Fernandez-Viladrich P, Pujol R. Multiple liver abscesses due to Yersinia enterocolitica discloses primary hemochromatosis: three cases reports and review. Clin Infect Dis. 1994;18(6):938-941.
7. Capron JP, Capron-Chivrac D, Tossou H, Delamarre J, Eb F. Spontaneous Yersinia enterocolitica peritonitis in idiopathic hemochromatosis. Gastroenterology. 1984; 87(6):1372-1375.
8. Porter JB, Garbowski M. The pathophysiology of transfusional iron overload. Hematol Oncol Clin North Am. 2014;28(4):683-701.
9. Armitage AE, Moran E. HIV-associated tuberculosis: does the iron-regulatory hormone hepcidin connect anemia with poor prognosis? J Infect Dis. 2016;213(1):3-5.
10. Arezes J, Jung G, Gabayan V, et al. Hepcidin-induced hypoferremia is a critical host defense mechanism against the siderophilic bacterium Vibrio vulnificus. Cell Host Microbe. 2015;17(1): 47-57.
11. Evans RW, Rafique R, Zarea A, et al. Nature of non-transferrin-bound iron: studies on iron citrate complexes and thalassemic sera. J Biol Inorg Chem. 2008;13(1):57-74.
12. Bernthal NM, Stavrakis AI, Billi F, et al. A mouse model of post-arthroplasty Staphylococcus aureus joint infection to evaluate in vivo the efficacy of antimicrobial implant coatings. PLoS One. 2010;5(9):e12580.
13. Esposito BP, Breuer W, Sirankapracha P, Pootrakul P, Hershko C, Cabantchik ZI. Labile plasma iron in iron overload: redox activity and susceptibility to chelation. Blood. 2003;102(7): 2670-2677.
14. Carniel E. The Yersinia high-pathogenicity island: an iron-uptake island. Microbes Infect. 2001;3(7): 561-569.
15. Bottone EJ. Yersinia enterocolitica: overview and epidemiologic correlates. Microbes Infect. 1999; 1(4):323-333.
16. Schubert S, Rakin A, Heesemann J. The Yersinia high-pathogenicity island (HPI): evolutionary and functional aspects. Int J Med Microbiol. 2004; 294(2-3):83-94.
17. Kwiecinski J, Na M, Jarneborn A, et al. Tissue plasminogen activator coating on surface of implants reduces Staphylococcus aureus biofilm formation. Appl Environ Microbiol. 2015;82(1): 394-401.
18. Lin MH, Shu JC, Huang HY, Cheng YC. Involvement of iron in biofilm formation by Staphylococcus aureus. PLoS One. 2012;7(3): e34388.
19. Schaible UE, Collins HL, Priem F, Kaufmann SH. Correction of the iron overload defect in beta-2microglobulin knockout mice by lactoferrin abolishes their increased susceptibility to tuberculosis. J Exp Med. 2002;196(11): 1507-1513.
20. Rostoker G, Vaziri ND, Fishbane S. Iatrogenic iron overload in dialysis patients at the beginning of the 21st century. Drugs. 2016;76(7):741-757.
21. Ware RE, de Montalembert M, Tshilolo L, Abboud MR. Sickle cell disease [published online ahead of print 31 January 2017]. Lancet. doi:10.1016/S0140-6736(17)30193-9.
22. Brennt CE, Wright AC, Dutta SK, Morris JG Jr. Growth of Vibrio vulnificus in serum from alcoholics: association with high transferrin iron saturation. J Infect Dis. 1991;164(5):1030-1032.
23. Skaar EP, Humayun M, Bae T, DeBord KL, Schneewind O. Iron-source preference of Staphylococcus aureus infections. Science. 2004;305(5690):1626-1628.
24. Cornelissen CN. Transferrin-iron uptake by Gram-negative bacteria. Front Biosci. 2003;8: d836-d847.
25. Kim A, Fung E, Parikh SG, et al. A mouse model of anemia of inflammation: complex pathogenesis with partial dependence on hepcidin. Blood. 2014;123(8):1129-1136.
26. Michels KR, Zhang Z, Bettina AM, et al. Hepcidin-mediated iron sequestration protects against bacterial dissemination during pneumonia. JCI Insight. 2017;2(6):e92002.
27. Brissot P, Ropert M, Le Lan C, Loréal O. Non-transferrin bound iron: a key role in iron overload and iron toxicity. Biochim Biophys Acta. 2012; 1820(3):403-410.
28. Belotti A, Duca L, Borin L, et al. Non transferrin bound iron (NTBI) in acute leukemias throughout conventional intensive chemotherapy: kinetics of its appearance and potential predictive role in infectious complications. Leuk Res. 2015;39(1): 88-91.
29. Arifin AJ, Hannauer M, Welch I, Heinrichs DE. Deferoxamine mesylate enhances virulence of community-associated methicillin resistant Staphylococcus aureus. Microbes Infect. 2014; 16(11):967-972.
30. Lesic B, Foulon J, Carniel E. Comparison of the effects of deferiprone versus deferoxamine on growth and virulence of Yersinia enterocolitica. Antimicrob Agents Chemother. 2002;46(6): 1741-1745.
31. Seok J, Warren HS, Cuenca AG, et al; Inflammation and Host Response to Injury, Large Scale Collaborative Research Program. Genomic responses in mouse models poorly mimic human inflammatory diseases. Proc Natl Acad Sci USA. 2013;110(9):3507-3512.